Kristin Louise A. Wilhelmsen

AgaTech ASA engages in the provision of investment advisory services. It operates through the following segments: Capital Markets, Investment Management and Others. The Capital Markets segment covers the group's activities subject to licenses within corporate finance, institutional sales and product development. The Investment Management segment activities represent a broad spectrum of management services, including investor relations and business operations. The Others segment engages in group administrative services within finance and economy, personnel, IT, communications and markets. The company was founded in 1990 and is headquartered in Oslo, Norway

Weifa ASA engages in the development, production and sales of medicines and other health products. Its products include medicines for pain relief, cough and cold, nutraceuticals, and dermatology. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway.

Watrium AS engages in active, long-term ownership of a global financial portfolio, industrial assets and top-tier commercial property. The company was founded in 2002 and is headquartered in Oslo, Norway.

Weifa AS operates as a pharmaceutical company. The firm supplies non-prescription, over the counter medicines, and lifestyle products. It offers medicines for pain, fever, muscle and joint, colds, wound, as well as vitamins, minerals, and prescription products. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway.

Flexiteek International AS leases intellectual property. The private company is based in Sandnes, Norway.

Part of Nansen Capital Partners AS, First Fondene AS is a capital management company based in Oslo, Norway. First Fondene offers various equity, fixed income, and combination funds with an active management style. The Norwegian company's flagship fund, FIRST Focus, aims to provide investors with the best risk-adjusted returns over time by investing in a focused but diversified portfolio of undervalued companies. The company was founded in 2007. Erik Haugland has been the CEO of the company since 2016.

Nordic & Europe Health Invest AS target companies primarily from the Nordic Region, but will consider investments in other Northern Europe countries. It will invest between NOK 100 million and NOK 150 million in each company and will make follow-up investments. It seeks a controlling and non-majority stake position in firms with the health care sector such as pharmaceutical/nutraceuticals, diagnostics, novel products for lowering of health care spending, medical devices and healthcare providers. Occasionally it will invest up to 20 % in early stage companies.